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Pneumocystis jirovecii is an airborne human-speciﬁc ascomycetous fungus responsible for Pneumocystis pneumo-
nia (PCP) in immunocompromised patients, affecting N500,000 patients per year (www.gafﬁ.org). The under-
standing of its epidemiology is limited by the lack of standardised culture. Recent genotyping data suggests a
limited genetic diversity of P. jirovecii. The objective of the study was to assess the diversity of P. jirovecii across
European hospitals and analyse P. jirovecii diversity in respect to clinical data obtained from the patients.
Genotypingwas performed using six already validated short tandem repeat (STR)markers on 249 samples (me-
dian: 17 per centre interquartile range [11−20]) from PCP patients of 16 European centres.
Mixtures of STR markers (i.e., ≥2 alleles for ≥1 locus) were detected in 67.6% (interquartile range [61.4; 76.5]) of
the samples. Mixture was signiﬁcantly associated with the underlying disease of the patient, with an increased
proportion in HIV patients (78.3%) and a decreased proportion in renal transplant recipients (33.3%) (p b
0.001). The distribution of the alleles was signiﬁcantly different (p b 0.001) according to the centres in three
out of six markers. In analysable samples, 201 combinations were observed corresponding to 137 genotypes:
116 genotypes were country-speciﬁc; 12 in two; six in three; and two in four and one in ﬁve countries. Nine ge-
notypes were recorded more than once in a given country. Genotype 123 (Gt123) was signiﬁcantly associated
with France (14/15, p b 0.001) and Gt16 with Belgium (5/5, p b 0.001). More speciﬁcally, Gt123 was observed
mainly in France (14/15/16 patients) and in renal transplant patient (13/15).
Our study showed the wide population diversity across Europe, with evidence of local clusters of patients
harbouring a given genotype. These data suggest a speciﬁc association between genotype and underlying disease,
with evidence of a different natural history of PCP in HIV patients and renal transplant recipients.
©2017 TheAuthors. Publishedby Elsevier B.V. This is an open access article under the CCBY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Pneumocystis jirovecii is a life-threatening atypical fungal organism
for which our knowledge of its epidemiology and basic biology is limit-
ed, largely due to an inability to reproducibly culture themicroorganism
in vitro (Thomas and Limper, 2007). Pneumocystis species has been
coevolving with each mammal species for 100 millions years leading
to the speciﬁcity of P. jirovecii to humans (Aliouat-Denis et al., 2008). In-
dividuals are exposed to P. jirovecii in childhood, with N80% of children
being seropositive before the age of 2 years (Bishop and Kovacs, 2003;
Meuwissen et al., 1977; Peglow et al., 1990; Pifer et al., 1978; Vargas
et al., 2001). This organism is therefore considered as a pulmonary res-
ident of immunocompetent individuals who carry P. jirovecii, at least
transiently, in their respiratory tract (Gigliotti and Wright, 2012). P.
jirovecii can then circulate constantly between normal hosts as sug-
gested by the high proportion of mixed infections (Alanio and
Bretagne, 2017).
Genotyping systems have been developed in the last 20 years to ex-
plore the pathophysiology of the infection (Pneumocystis pneumonia,
PCP) and to trace the transmission of P. jirovecii in speciﬁc areas such
as hospital wards. PCR single strand conformation polymorphism
(PCR-SSCP) of nuclear and mitochondrial loci allowed the analysis of
several isolates associated with clustered infections (Hauser et al.,
1997a,b; Nahimana et al., 2000). Sequencing of internal transcribed
spacers (ITS), which locus is unique in the nuclear genome
(Helweg-Larsen et al., 2001; Le Gal et al., 2012; Tsolaki et al., 1996),
and sequencing of mitochondrial large subunit ribosomal loci have
also been used (Keely et al., 1995). A multi-locus sequence typing
(MLST) approach has also been implemented (Keely and Stringer,
1996) and a MLST scheme was optimized based on the sequencing of
eight nuclear and mitochondrial loci (Maitte et al., 2013). The number
of different genotypes described in literature was 43 using the PCR-
SSCP method (Hauser, 2004), although N60 genotypes were identiﬁed
using ITS sequencing methods (Lu and Lee, 2008). Single nucleotide
polymorphism (SNP) was also studied using single nucleotide primer
extension in mitochondrial and genomic genes (Alanio et al., 2015;
Esteves et al., 2011) and more recently, using ultra-deep-pyrosequenc-
ing (UDPS) to study three mitochondrial SNPs (Alanio et al., 2016).
An important feature of genotypingmethods is the sensitivity when
detecting minority alleles, since for P. jirovecii genotyping is performed
directly on clinical samples because of the absence of culture. Although
mixtures of two ormore genotypes in one clinical sample have been re-
ported, the rate of mixed infection varied from 5 to 25% using classical
Sanger DNA sequencing (Esteves et al., 2010, 2008; Helweg-Larsen et
al., 2001) and single nucleotide primer extension, respectively (Alanio
et al., 2015; Esteves et al., 2011), to 70% by both PCR-SSCP (Hauser et
al., 2001) and Microsatellite Length Polymorphism (MLP)
(Gits-Muselli et al., 2015; Parobek et al., 2014), and to N90% of the sam-
ples using UDPS (Alanio et al., 2016).
To avoid sequencing and to test genetic variation differently to SNPs,
MLP schemes have also been recently developed, targeting Short Tan-
dem Repeat (STR) markers (Gits-Muselli et al., 2015; Parobek et al.,
2014) identiﬁed once the P. jirovecii genome was available (Cissé et
al., 2012). The ﬁrst MLP genotyping method developed by Parobek et
al., based on eight genetically unlinked markers, was used to genotype
63 clinical isolates from Africa (Uganda), Europe (Spain), and USA
(San Francisco) (Parobek et al., 2014). A different MLP genotyping
method based on six other STR markers was more recently developed
(Gits-Muselli et al., 2015). This last MLP typing method is reproducible,
cheap, with a high throughput and a high discriminatory power (DP) of
0.992 making it interesting to investigate transmission in hospital set-
tings (Gits-Muselli et al., 2015; Robin et al., 2017).
The objective was to understand the diversity of this organism
across Europe and to get insight into the geographical and temporal
evolution of the different genotypes. The diversity of P. jirovecii isolates
responsible for PCP across different European countries (n = 12) was
investigated, in order to detect themost prevalent genotypes and to de-
tect possible transmission within or between centres (n = 16) using
this novel MLP typing method (Gits-Muselli et al., 2015).
2. Material and Methods
2.1. Patients and Clinical Samples Collection
Sixteen European centres were asked to send 25 frozen DNA sam-
ples obtained from respiratory samples from patients with PCP over
the minimum period of time. These 16 centres across Europe included
ﬁve French centres (Amiens University Hospital [Nth-FR]; Brest Univer-
sity Hospital, Brest [We1-FR], Nantes University Hospital, Nantes [We2-
FR]; Hôpital de la Croix-Rousse, Lyon [Ea-FR] and Saint-Louis University
Hospital, Paris [Ce-FR]), and one centre per country for Belgium [BE]
(University Hospitals Leuven), Czech Republic [CZ] (University Hospital
Brno), Denmark [DK] (Rigshospitalet-Copenhagen University Hospital),
Germany [DE] (University Hospital Cologne), Italy [IT] (University of
Roma “Tor Vergata”), Poland [PL] (WroclawMedical University), Portu-
gal [PT] (Instituto de Higiene e Medicina Tropical, Universidade NOVA
de Lisboa), Spain [ES] (Hospital Universitario Virgen del Rocío, Sevilla),
Switzerland [CH] (Lausanne University Hospital), The Netherlands
[NL] (Radboud University Medical Centre, Nijmegen), and United King-
dom [UK] (Public Health Wales, Microbiology Cardiff) (Fig. 1).
The samples consisted of DNAs extracted at the time of PCP diagno-
sis in the corresponding centre following local DNA extraction and stor-
age procedure except for DK and ES who send frozen respiratory
specimens which DNA was extracted in Ce-FR as already reported
(Gits-Muselli et al., 2015). The samples were bronchoalveolar lavage
(BAL) ﬂuids (85.1%) and sputa (14.9%). The microscopy and local PCR
results, including the quantiﬁcation cycle (Cq) when quantitative PCR
(qPCR) assays had been used were recorded. Data regarding date of
PCP diagnosis, demographics, country of birth, and underlying disease
or condition (HIV-infection, haematological malignancy, solid organ
transplant, solid cancer, or immunological disorders) were collected.
Only ﬁve paediatric cases were included.
2.2. STR Genotyping
The six STRs markers (#022, #108, #138, #189, #278, and #279)
were ampliﬁed separately as previously described (Gits-Muselli et al.,
2015). Brieﬂy, the forward primers were tagged with FAM, HEX or
ATTO565 ﬂuorophores. PCR reactions were performed on a GeneAmp
PCR System 9700 Thermocycler (Applied Biosystems) in a ﬁnal volume
of 20 μL. The reaction mixture was composed of 1× AmpliTaq Gold
buffer (Life technologies) with 0.25 μM of each primer, 2.5 mM of
MgCl2, 0.8 μM of dNTPs, 0.25 UI of AmpliTaq Gold polymerase (Life
technologies) and 2 μL of DNA. The PCR protocol was 10 min at 95°,
followed by 35 cycles of 30 s at 95 °C (denaturation), 30 s at 56° (primer
annealing) and 60 s at 72 °C (extension) followed by a ﬁnal extension of
10min at 72 °C. A calibration sample was used in each PCR run as an in-
ternal control. Then, 2 μL of the PCR product was prepared for fragment
analysis by the addition of 18 μL of formamide (Life Technologies)
and 1 μL of Genescan-500 LYZ Size Standard (Life Technologies). The
lengths of the PCR fragments were determined by capillary electropho-
resis (50 mm) on an ABI 3500 genetic analyser using denaturing poly-
mer POP-7 (Life Technologies) at 60 °C. Analysis was performed with
the ABI Gene mapper v4.1 software (Life Technologies).
2.3. Genotyping Analysis
The samplewas included in the study if all sixmarkerswere success-
fully ampliﬁed and analysed. A unique combination of all six markers
deﬁned a genotype (Gt) or a strain, that was called fungal individual
(FI), since culture is not possible in P. jirovecii. Gt could be delineated
if (i) each of the six STR markers were pure (no additional peak
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corresponding to a smaller or larger amplicon) or (ii) only one marker
hadmultiple amplicons (one to three additional detectable peaks corre-
sponding to a smaller or larger amplicon). In the latter case, the inter-
pretation was mixture of two or three FIs from genotypes different in
only one marker. When several alleles were observed for N2 loci, Gt
and FIs could not be individualized and delineated. Relatedness be-
tween genotypes was investigated by comparing allelic proﬁles with
the minimum spanning tree (MStree) method (BioNumerics software
v6.5, Applied Maths Inc., Austin, TX) as previously described (Gits-
Muselli et al., 2015). Brieﬂy, alleles were treated asmultistate categories
based on an inﬁnite allele model (i.e., all changes are equally likely). Ge-
netic clusters were deﬁned as group of genotypes that have a single al-
lelic mismatch with at least one other member of the group. Singletons
were deﬁned as genotypes thatwere not grouped into clonal complexes
(at least two allelic mismatches with other genotype). The number of
repeat differences between ancestral and derived alleles was computed
for each link of one mismatch along the Minimum Spanning Tree. The
classical criterion of one allelic mismatch to group genotypes in clonal
complexes was used (Feil, 2004). The discriminatory power (DP) as an
indicator of the genetic diversity was calculated with Simpson's diversi-
ty index, as described previously (Hunter and Gaston, 1988).
2.4. Statistical and Graph Analysis
Chi-2 test and Fisher's exact test were used for contingency tables
analyses for calculation of statistical association between genotypes
andmixtures, genotypes and clinical data, mixture and clinical data, ge-
notypes and centres mixture and centres. Median and interquartile
ranges are described in the text. P values of b0.05 were considered sig-
niﬁcant. Graphs (grouped columns of the alleles recorded in the
different centres) and statistical analyses were performed by using
Prism 6.0 (GraphPad Software Inc., La Jolla, CA, USA).
2.5. Ethics Statement
This study was a non-interventional study with no change in the
usual procedures. Biological material and clinical data were obtained
only for standard diagnostic following physicians' prescriptions with
no speciﬁc sampling. For France, according to the French Health Public
Law (CSP Art L1121-1.1), such protocol does not require approval of
an ethics committee and is exempted from speciﬁc informed consent
application. However, all patientswere informed and signed documents
for non-opposition to this study. Data ﬁle was declared and approved to
the French data protection agency (no. 1818924). In speciﬁc countries,
approval from local ethic committee was obtained when required.
3. Results
A total of 361 samples from 361 patients with a median of 25 sam-
ples per centre [19–25], obtained from 1998 to 2015 (97.2% collected
after 2009), were sent to Saint-Louis Hospital, Paris, France for genotyp-
ing. All samples hadmicroscopic evidence of the presence of asci or tro-
phic forms using standard staining or anti-Pneumocystis
immunoﬂuorescence, or were PCR-positive with high fungal load ac-
cording to the local qPCR assay. Of these 361 DNA samples, the six STR
markers were correctly ampliﬁed in 249 (69.0%) samples from 249 pa-
tients (Fig. 2). Sampleswith ampliﬁcation failure of one ormore of the 6
markers (112/361; 31%) were further excluded. The median number of
successfully ampliﬁed samples per centre was 17 (11−20). The qPCR
assays performed locally on these sampleswere heterogeneous (mainly
Fig. 1. Distribution of centres (spot) and countries (grey) who participated to this study. The abbreviation of the centre is indicated within each spot.
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in-house PCR targeting either mtLSU, Kex, or MSG genes, including al-
ready published assays (Alanio et al., 2011; Larsen et al., 2002; Totet et
al., 2003). The median Cq was 25 [22–28]. Male/female ratio was 1.83
and the median age was 55 years. The patients' predisposing diseases
or conditions were AIDS (36.9%), haematological malignancy (19.7%),
renal transplantation (13.3%), and other causes of immunosuppression
(25.3%), with this piece of information not available for 4.8% of cases.
3.1. Mixtures of Genotypes
Genotyping analysis revealed that 160 out of 249 (64.2%) samples
containedmixtures of genotypes including 56 samples harbouringmul-
tiple alleles at one locus and 104 samples harbouringmultiple alleles at
≥2 loci (Fig. 2). Of note, 61.3% of the 31 excluded samples because of one
locus ampliﬁcation failure also containedmixed genotypes. Themedian
percentage of mixtures per centre was 67.5%, interquartile range [61.4;
76.5]with a trend toward a different proportion ofmixture in the differ-
ent centres (Chi2 test; p=0.090). Themixtureswere signiﬁcantly asso-
ciated with the underlying disease (p b 0.001), with an increased
proportion of mixture in HIV-positive patients (78.3%) compared to
HIV-negative patients (55.9%, p b 0.001) and a decreased proportion
ofmixtures in renal transplant recipients (33.3%) compared to other pa-
tients (69.6%, p b 0.001).
3.2. Genotyping Analysis
Based on the analysis of the 249 samples, 3 distinct alleles were ob-
served for STR #022, 3 for #108, 7 for #138, 15 for #189, 11 for #278,
and 8 for #279. The distribution of the alleles at each centre is shown
in Fig. 3. The distribution of alleles was signiﬁcantly different according
to the centre for STR #138 (p= 0.011), #278 (p= 0.006), and #279 (p
b 0.001).
Genotype assignment was performed for 145 samples harbouring
one allele for each locus (n = 89) or 2–3 alleles for one locus only
(n = 56). To ascribe the different peaks to a given genotype was
not possible in samples harbouring mixtures at more than one marker
(n = 104). Therefore, genotype distribution analysis was performed
on 145 samples out of the initial 249 samples (58%) and revealed 137
genotypes from 201 FIs (Fig. 4). MST analysis showed a repartition in
one major complex (n = 128 genotypes), two minor clonal complexes
(2 and 3 genotypes, respectively), and singletons (n = 4 genotypes)
(Fig. 4A). Gt33 (found in Ce-FR,We2-FR, BE, ES andDE)was the founder
genotype from which all genotypes derived with 11 genetic branches
(Br1 to Br11) generated from it. From these 11 branches, four main
branches (Br1 to Br4) can be delineated (Fig. 4A). Br1 was composed
of 16 genotypes (31 FIs), Br2 of 32 genotypes (50 FIs), Br3 of 50
genotypes (70 FIs), and Br4 of 14 genotypes (15 FIs). The proportion
of solid organ transplant patients signiﬁcantly increased in Br1 com-
pared to the other underlying diseases (42.1% vs. 6.8%; p b 0.001) and
signiﬁcantly decreased in Br3 compared to the other underlying
diseases (4.8% vs. 15.5%; p = 0.044) (Fig. 4B). The repartition of the
samples regarding the country of origin of the patients and date of
recovery did not show any clustering (data not shown).
The DPwas 0.991 based on the analysis of 201 FIs. Since highly inde-
pendent isolates must be used for DP calculation (Hunter and Gaston,
1988), renal transplant recipients harbouring the same genotype were
excluded because direct transmission between patients could be
suspected. Thus, 12 FIs from three centreswere excluded from this anal-
ysis (Gt123 [-7]; Gt16 [-4]; Gt94 [−2]) and the ﬁnal DP was 0.995.
3.3. Geographical Distribution of the Genotypes
Of the 137 genotypes, 116 (84.7%) were individual to a single coun-
try, 12 (8.8%) in two, six (4.4%) in three, two (1.5%) in 4 and one (0.7%)
in ﬁve countries (Table 1, Supplementary Tables 1 and 2). Of note, one
genotype (Gt56) was found in seven different centres (ﬁve countries).
The DP varied from centre to centre with a median at 1.00 (range
[0,93–1.00]. Eight centres (Ea-FR, CH, ES, PT, IT, DK, DE, CZ) had a DP
at 100% and three centres had a DP b0.96 (We1-FR [0.931], UK [0.955]
and BE [0.947]).
Ten genotypes were foundmore than once in a given country. Nota-
bly, Gt94was found in 4/19 (15.8%) patients in UK, Gt16was found in 6/
19 (31.6%) patients in Belgium, and Gt123was found in 15/108 (13.9%)
patients in France. Of note, Gt94 and Gt16were found in three countries
respectively (four centres for Gt94) and Gt123 in two countries (ﬁve
centres).
Two out of the four patients harbouring Gt94 were renal transplant
recipients representing all the renal transplant recipients of the cohort
(Table 2). Five out of the six patients with Gt16 were renal transplant
recipients and Gt16 was found in 5/9 (55.6%) renal transplant recip-
ients tested. Gt123 was found in 15 patients including 14 from west,
north and centre of France (six from centre We1-FR, 5 from centre
We2-FR and 2 from No-FR and 2 from Ce-FR). No Gt123 was ob-
served in Ea-FR. Among the 15 French patients harbouring Gt123,
13 (86.7%) were from renal transplant patients sampled from 2009
to 2015. In the centres with presence of Gt123, amedian of 66.7% (in-
terquartile range: 54.2–91.7) of the renal transplant recipients and
16.2% (interquartile: range 8.4–26.3) of the other patients tested
harboured the Gt123. Indeed, an increased representation of Gt123
was observed in SOT patients compared to other underlying diseases
(p b 0.001).
Fig. 2. Flow chart representing the number of samples analysed and classiﬁed in this study. The number of isolates harbouring pure (one allele per locus), genotypablemixtures (≥2 alleles
for one locus) and non-genotypable mixtures (≥2 alleles for ≥2 loci).
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3.4. Temporal Distribution of the Genotypes
Gt123 has been isolated from 2009 to 2015, ﬁrst in We1-FR (2009–
2011) and then in other French centres (We2-FR, No-FR and Ce-FR) be-
tween 2012 and 2015 (Table 1, Fig. 5). The German Gt123 was sampled
in January 2013. Two 30–40 year-old patients harbouring pure Gt123
were born in Caribbean islands and in Algeria before kidney transplan-
tation was performed in Ce-FR in 2014 and 2015, respectively.
We found only two other genotypes that were recovered N6 times
between 2012 and 2015. In comparison, Gt16 (n = 6) was recovered
two times in 2012, three in 2013 and one in 2014 and not in 2015.
Gt94 was not recovered in 2012 and 2013 and recovered four times in
2014 and twice in 2016.
4. Discussion
The present P. jirovecii genotyping study is the ﬁrst one dealing with
several European countries and using anMLP typing (Gits-Muselli et al.,
2015). In analysing 249 cases of PCP recruited from 16 centres across 12
European countries, ourmain ﬁndings were the large proportion of PCP
cases harbouring mixtures of FIs, the limited genetic evolution of P.
jirovecii across Europe, and the possible enrichment of genotypes at
some centres, possibly linked to the underlying disease of the patient.
The association between underlying disease/conditions and mixed
infection has never been reported. We observed a signiﬁcant increase
of samples containing multiple FIs in HIV patients and a signiﬁcant de-
crease of samples containing multiple FIs in renal transplant patients.
This could be explained by the evolution of HIV infection over several
years with a progressive decrease of about 61 CD4 T-cells/μL per year
(Wolbers et al., 2010), that could allow the HIV-positive patient to in-
hale numerous and various P. jirovecii genotypes over the course of
HIV infection. Then, PCP would occur with a mixture of genotypes en-
countered by the patient over the last 5–10 years. Conversely, renal
transplant recipients have a controlled period of immunosuppression,
resulting in a shorter duration for exposure to P. jirovecii, during
which P. jirovecii would be able to proliferate rapidly, resulting in
acute disease (124 to 170 days) (Phipps et al., 2011), the starting
point potentially being the stop of anti-PCP prophylaxis (de Boer et al.,
2011). Similar resultswere recently reportedwith a dominant genotype
responsible for an outbreak in a haematology ward suggesting a recent
acquisition of the epidemic genotype (Robin et al., 2017). Since PCP oc-
curs when prophylaxis is stopped (de Boer et al., 2011), this raises the
question of life-long administration of anti-PCP prophylaxis in at-risk
patients, especially in renal transplant recipients with prolonged
immunodepression (Alanio and Bretagne, 2017; Goto et al., 2017;
Wang et al., 2012). However, the fungal load is known to be lower in
HIV-negative patients (Alanio et al., 2011; Cordonnier et al., 2016;
Roux et al., 2014) than in HIV-positive patients and a low fungal load
could negatively inﬂuence the detection of mixed infections. Thus,
only the most numerous would be evidenced whereas multiple geno-
types would be nevertheless present. Using a single nucleotide exten-
sion method, which can detect minority alleles until 5–10%, the low
fungal loadswere not associatedwith lessmixtures than the high fungal
loads, suggesting an independent association between number of geno-
types with underlying diseases rather than with the fungal load (Alanio
et al., 2015). To avoid biases in the interpretation of the results, it was
decided not to genotype PCP cases harbouring mixtures of isolates
with more than one allele in more than one marker. To interpreted
these mixtures, as proposed by other authors (Parobek et al., 2014),
would have introduced genotypes which the reality was impossible to
ascertain. In addition, in 31% of the samples it was not possible to obtain
all makers. This was likely as a result of low DNA fungal loads, degrada-
tion of DNA upon storage or shipment, or DNA extraction issues. With
Fig. 3.Allele distribution for the 249 samples from the 16 European centres. The number of isolates harbouring a speciﬁc allele size was collected per centre and pooled as a function of the
observed allele sizes for each marker. Coloured boxes allowed identiﬁcation of the centre.
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these restrictions to the 69% of analysable samples, we found a global
prevalence of mixture at 64% (160/249), in the same order of the 70%
of mixtures previously reported (Alanio et al., 2016; Gits-Muselli et al.,
2015; Hauser et al., 2001; Parobek et al., 2014). However,more sensitive
methods such as ultra deep pyrosequencing have detected mixtures in
up to 92% of the samples (Alanio et al., 2016). These results suggest, as
already described (Hauser et al., 2001; Parobek et al., 2014), that PCP
is frequently due tomultiple genetically distinct organisms, that are un-
likely to be diploid. Indeed, P. jirovecii is known to be a haploid organism
(Cissé et al., 2012;Wyder et al., 1998), although lack of detailed genetic
analyses prevents the detection of DNA insertion or deletion leading to
aneuploidy. However, in the situation where multiple alleles at one
locus are observed (n=56), duplication of part of the genome, resulting
in aneuploidy, could be responsible for this diversity. Microevolution of
part of the P. jirovecii organisms could also explain this phenomenon.
Even if the DP of the method calculated from this study is N0.99
(DP = 0.995, as compared to 0.992 in our previous study (Gits-Muselli
et al., 2015)), the distance between P. jirovecii genotypes remains low
using our MLP typing method, resulting in a limited number of genetic
groups. This low genetic disparity had been suggested by Parobek et al.
when they found that P. jirovecii samples from San Francisco (n = 49)
and from Spain (n = 29) had limited genetic differentiation (Parobek
et al., 2014), as comparedwithUgandan samples. This limited genetic di-
vergence of European P. jirovecii isolates could be explained by speciﬁc
aspects of P. jirovecii biology. Indeed, P. jirovecii is considered as an obli-
gate fungal biotroph harbouring parasitic behaviour (Cissé et al., 2014),
that may intrinsically limit the opportunities to diverge genetically.
Loss of genes is the main characteristics of P. jirovecii genome evolution
compared to its last common ancestor Taphrina deformans (Cissé et al.,
2014; Ma et al., 2016). The DNA polymerases or the DNA repair machin-
ery of P. jirovecii could also speciﬁcally restrict genetic diversity.
Our study highlighted that transmission may occur in speciﬁc cen-
tres (We1-FR and Gt123, UK and Gt94; BE and Gt16) or within different
centres of a given country (FR centres andGt123). This observation sug-
gests that amore systematic genotyping analysis of PCP cases could lead
to identiﬁcation of clustered cases and to the implementation of preven-
tion procedure to stop circulation of a speciﬁc Gt at a speciﬁc place. To
our knowledge, some centres (including the CHU Vaudois, Lausanne,
Switzerland and Necker University Hospital, Paris, France) already use
air prevention measures such as mask wearing when a case of PCP is
diagnosed.
Interestingly, the percentage of samples harbouring a mixture of FIs
at a given centre dropped from 70% in average to 36–42% (We1-FR and
BE). This suggests nosocomial PCP as a result of recent exposure to a
Table 1
The number of different genotypes observed across countries and centres.
Number of countries where identical genotypes were
recovered
1 2 3 4 5 6 7
Nb of genotypes (n = 137) 116 12 6 2 1 0 0
Number of centres where identical genotypes were
recovered
1 2 3 4 5 6 7
Nb of genotypes (n = 137) 113 13 6 2 2 0 1
Fig. 4.Minimumspanning tree analysis of 137 genotypes from145 samples (201 fungal individuals) harbouring a uniquegenotype (one allele permarker) ormultiple genotypes (multiple
alleles in onemarker). Thenumber of allelicmismatches among STR proﬁleswasused as distance. Each circle corresponds to one genotype (Gt),with its arbitrary number indicatednext to
it. The size of the circle is correlated with the number of isolates possessing the corresponding genotype, from one (smallest circle) to thirteen (Gt123). Dark, dashed and thin connecting
bars correspond to one, 2 or N2 different markers observed between linked genotypes. Coloured zones surrounding some groups of circles indicate that these proﬁles belong to the same
genetic cluster,meaning that they have a single allelicmismatchwith at least one othermember of the group. Cluster 2, whichwas signiﬁcantly associatedwith renal transplant recipients,
is shown by a dashed line. The colour of the circles indicates the underlying disease of the patient in whom this speciﬁc genotype was recovered (Green, HIV patient; Red, haematology
patient; Purple, renal transplant recipient; Yellow, other cause of immunosuppression).
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given P. jirovecii genotype. This also suggests that a given genotype
could have a biological advantage over other genotypes resulting in an
increased number of patients with PCP due to this genotype. This hy-
pothesis could be reinforced by the fact that Gt123 was responsible for
15 cases of PCP across France that could be considered independent
since no contact between these patients could be imagined (renal trans-
plant patients, transplanted and always followed in separate centres).
Interestingly, Gt123 was not observed in patients with other causes of
immunosuppression, suggesting that Gt123 could not be considered
as highly prevalent or currently circulating in France. Gt123 could be
well adapted to renal transplant patient immunodeﬁciency and Gt123
could have spread from the West of France (We1-FR) from 2009 to
2011 to other centres (We2-FR then No-FR and Ce-FR) between 2012
and 2015 (Fig. 5). A similar hypothesis has already been suggested by
Sassi et al. (Sassi et al., 2012), who described two distinct outbreaks of
PCP in renal transplant recipients due to the same genotype in Zurich
(Switzerland) and Munich (Germany) (Hauser et al., 2012; Sassi et al.,
2012). These cities are located about 300 km apart, which is almost
half the distance between the centres in We1-FR and Ce-FR (592 km).
In addition, identical genotypes were detected in different countries,
with a total of 21/134 (15.3%) samples harbouring the same genotype
found in more than one country, with the founder genotype (Gt33)
and the Gt56 found in ≥4 countries (from Seville, Spain to Cologne, Ger-
many, 2230 km apart). This suggests that some genotypes could have
disseminated across Europe, or that this typing method is not discrimi-
native enough to observe differences between those isolates (Alanio et
al., 2017). This observation and ours suggest that a given P. jirovecii ge-
notype is able to circulatewithin an area of at least of 600 km(Hauser et
al., 2012; Sassi et al., 2012). It is possible that some immunocompro-
mised patients were exposed to this speciﬁc genotype through contact
with immunocompetent carriers, to rather than direct contact between
renal transplant recipients located in different centres.
When analysing themost frequent genotype (Gt123), the difference
between the date of the ﬁrst (28th May 2009) and the last (23th April
2015) observation was 2156 days (i.e., 5.9 years) (Fig. 5). If one
hypothesises that interhuman transmission is the main mechanism in
PCP, this is potentially the longest period of transmission of PCP ever re-
ported and this ﬁnding raises the issue of the dissemination of a given
genotype over time in different places.When studying a single hospital,
the duration of transmission of a given genotype varied from 1 to
2 months to 31 months (2.6 years) (Yiannakis and Boswell, 2016) or
32.2 months (2.7 years) (Gits-Muselli et al., 2015). This possible long
Fig. 5. Temporal and geographical distribution of Gt123 in France. The number of days between the ﬁrst sample and the corresponding sample harbouring Gt123 is reported on the X axis
(Panel A). Most probable hypothesis regarding the temporal and geographical circulation of Gt123 in France (Panel B). The number of cases in the corresponding centre is indicated in the
circles. Each centre is coloured adequately as red for We1-FR; orange for We2-FR; green for Nth-FR and blue for Ce-FR and purple for Ea-FR.
Table 2
Characteristics of the patients and samples harbouring Gt16, Gt94 and Gt123 in their respective country.
Sample/patient n° Centre Type of
infection
Date of
recovery
Sample
type
Gender Age Underlying
disease
Country of origin of
the patient
Episodes Prophylaxis Genotype
4 Nth-FR Pure 19/08/13 BAL F 65 Renal transplant France First No 123
18 Nth-FR Pure 23/01/15 BAL M 58 Renal transplant France First No 123
28 We1-FR Pure 28/05/09 BAL M 55 Renal transplant France First no 123
31 We1-FR Pure 26/08/10 BAL F 56 Renal transplant France First no 123
33 We1-FR Pure 27/09/10 BAL M 45 Renal transplant France First no 123
34 We1-FR Pure 09/09/11 BAL M 55 Renal transplant France First na 123
40 We1-FR Pure 25/11/10 BAL M 55 Renal transplant France First no 123
43 We1-FR Pure 13/11/09 BAL M 26 Haematology France First yes 123
156 We2-FR Pure 10/10/13 BAL M 46 Renal transplant France First No 123
164 We2-FR Pure 19/07/14 BAL M 69 Other cause of immunosupression France First No 123
171 We2-FR Mixed 02/03/15 BAL F 26 Renal transplant France First na 123
175 We2-FR Pure 26/03/12 BA M 32 Renal transplant France First No 123
176 We2-FR Pure 08/06/12 BAL M 60 Renal transplant France First No 123
180 Ce-FR Pure 23/04/15 Sputum F 67 Renal transplant Algeria First No 123
183 Ce-FR Pure 17/10/14 BAL M 68 Renal transplant Caribbean island First No 123
46 UK Pure 02/03/15 BAL F 62 na UK na yes 94
49 UK Mixed 01/09/14 BAL M 52 HIV-infected UK na yes 94
52 UK Pure 13/03/14 BAL M 62 Renal transplant UK na na 94
59 UK Pure 17/03/15 BAL M 71 Renal transplant UK na na 94
231 BE Pure 11/09/12 BAL na na Renal transplant na na na 16
232 BE Pure 29/11/12 BAL F 65 Renal transplant Belgium First No 16
236 BE Pure 17/08/13 BAL F 47 Renal transplant Belgium First No 16
238 BE Pure 13/12/13 BAL M 59 Renal transplant Belgium First No 16
239 BE Mixed 01/07/13 BAL M 64 Haematology Belgium First No 16
243 BE Pure 07/05/14 BAL F 69 Renal transplant Belgium First No 16
BAL: Bronchoalveolar lavage; BA, Bronchial aspirate, IS: immunosuppression; na: not available.
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time of transmission may suggest that immunocompetent individuals,
such as health care workers, could serve as a potential reservoir, since
environmental reservoir is unlikely for this fungus (Alanio and
Bretagne, 2017). Thus, two patients of the present study harbouring
pure Gt123 were born and had lived N30 years in Algeria and in Carib-
bean islands before kidney transplantation was performed in Paris,
France. This Gt123 was probably acquired after the renal transplanta-
tion from recent exposure either by direct transmission or through a
third source. Whatever the ﬁnal mode of transmission, our ﬁnding ar-
gues against reactivation of resident P. jirovecii previously acquired in
their country of origin. Another argument for the recent acquisition of
a new genotype in PCP is our observation of some temporal relation-
ships between the genotype and the date of PCP (for example, 2012–
2013 and Gt16, or 2014–2015 and Gt94). However, a limit to be ac-
knowledged to our study on timing of transmission is that the samples
were obtained from patients managed from 1998 to 2015. In particular,
the centres with a low number of cases included the oldest cases. This
was inherent to the retrospective design of our study and the uneven
sampling prevents any deﬁnitive conclusion about the temporal evolu-
tion of the genotypes circulating across Europe. To address this ques-
tion, speciﬁc prospective studies should be implemented in various
European places.
In conclusion, the genetic diversity of P. jirovecii appears limited,
suggesting a constant exchange between human individuals and the si-
multaneous presence of several genotypes in a given individual. On this
constant exchange background, some temporal and geographical evolu-
tions of genotypeswere observed in independent centres suggesting re-
cent acquisition of new genotypes and more rapidly circulating
genotypes between immunocompromised patients. This reinforces the
supposed dynamic transmission of P. jirovecii between non-immuno-
compromised and immunocompromised hosts, the ﬁrst being reservoir
fromwhich new genotypes can be contracted by immunocompromised
patients and subsequently transmitted to other patients (Alanio and
Bretagne, 2017).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2017.06.027.
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